Ascendis Pharma A (ASND) Interest Income - Net (2014 - 2026)

Ascendis Pharma A has reported Interest Income - Net for 13 years, with the latest figure at -$73.4 million in Q1 2026.

• Quarterly Interest Income - Net fell 538.28% year-over-year to -$73.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$502.1 million (down 265.84% YoY) and the FY2025 annual result came in at -$516.9 million, down 149.07% from the prior year.
• Interest Income - Net grew to -$73.4 million in Q1 2026 per ASND's latest filing, from -$243.7 million in the prior quarter.
• Over five years, Interest Income - Net peaked at $16.8 million in Q1 2025 and troughed at -$243.7 million in Q4 2025.
• A 5-year average of -$59.2 million and a median of -$48.5 million in 2023 frame the typical range for Interest Income - Net.
• The sharpest annual moves came in 2022 and 2025: Interest Income - Net slumped 7191.3% in 2022, then soared 120.97% in 2025.
• Over 5 years, Interest Income - Net stood at -$8.3 million in 2022, then retreated by 17.53% to -$9.8 million in 2023, then plunged by 611.11% to -$69.3 million in 2024, then sank by 251.43% to -$243.7 million in 2025, then soared by 69.86% to -$73.4 million in 2026.
• According to Business Quant data, Interest Income - Net over the past three periods registered -$73.4 million, -$243.7 million, and -$85.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.